Search results
Results From The WOW.Com Content Network
Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer: Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%). Oxaliplatin: IV: Reacts with DNA, inducing apoptosis, non-cell cycle specific. Colorectal cancer, oesophageal cancer and gastric cancer
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
The American Cancer Society has found no evidence that antineoplastons have any beneficial effects in cancer, and it has recommended that people do not spend money on antineoplaston treatments. [136] Apitherapy – the use of products derived from bees, such as honey and bee venom, as a therapy. Apitherapy has been promoted for its anti-cancer ...
Increased risk of cancer. [32] Lumiracoxib (Prexige) 2007–2008 Worldwide Liver damage Lysergic acid diethylamide (LSD) 1950s–1960s Marketed as a psychiatric drug; withdrawn after it became widely used recreationally. Now illegal in most of the world. Mebanazine: 1975 UK Hepatotoxicity, drug intereaction. [3] Methandrostenolone: 1982
Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. [1] Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, [2] and PARP inhibitors such as olaparib. [3]
About a third of people with cancer in India use Ayurveda or other elements of AYUSH. [ 14 ] A 2000 study published by the European Journal of Cancer evaluated a sample of 1023 women from a British cancer registry who had breast cancer and found that 22.4% had consulted with a practitioner of complementary therapies in the previous twelve months.
PH-responsive tumor-targeted drug delivery; PHEC-66; Photodynamic therapy; Photostatin; Plasmonic nanoparticles; Predictive marker; Prehabilitation; Procarbazine; Prophylactic cranial irradiation; Management of prostate cancer
Treatment of adults with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test [2]